Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
NBIX
NBIX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NBIX News
Neurocrine Biosciences Releases Guidelines for Tardive Dyskinesia Treatment
4d ago
PRnewswire
Neurocrine Biosciences Appoints New Chief Technical Officer
Mar 17 2026
Newsfilter
Equifax Named 'Stock to Study' for May 2026 by BetterInvesting
Mar 06 2026
PRnewswire
Equifax Named 'Stock to Study' by BetterInvesting
Mar 06 2026
Newsfilter
Neurocrine Shares Drop 8% After Mixed Earnings Despite Strong Ingrezza Sales
Feb 12 2026
Newsfilter
Neurocrine Reports Q4 Earnings Miss Amid Strong Sales Growth
Feb 12 2026
Benzinga
Wall Street Analysts Adjust Ratings
Feb 12 2026
Benzinga
Neurocrine Biosciences Q4 2025 Earnings Call Highlights
Feb 12 2026
seekingalpha
Neurocrine Biosciences Q4 Earnings Analysis
Feb 11 2026
seekingalpha
Neurocrine Biosciences Reports Strong 2025 Financial Results
Feb 11 2026
Yahoo Finance
Neurocrine Biosciences Q4 Earnings Announcement Scheduled
Feb 10 2026
seekingalpha
Neurocrine Initiates Phase 2 Study for NBI-1065890 in Tardive Dyskinesia
Jan 26 2026
PRnewswire
Neurocrine Initiates Phase 2 Study for NBI-1065890 in Tardive Dyskinesia
Jan 26 2026
Newsfilter
Neurocrine Biosciences Presents Head-to-Head Data Showing INGREZZA's Superior VMAT2 Target Occupancy Over AUSTEDO XR
Jan 15 2026
PRnewswire
Neurocrine Biosciences Presents Head-to-Head VMAT2 Occupancy Data for INGREZZA vs AUSTEDO XR, Showing Nearly Double Potency
Jan 15 2026
Newsfilter
AbbVie Upgraded Price Target to $269 Despite 4% Stock Drop
Jan 06 2026
Benzinga
Show More News
